# US 2022/0016215 A1 · Gip receptor agonist peptide compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016215 A1
- Document ID: US20220016215A1
- Status: Published application
- Kind: A1
- Application number: 17/279,228
- Filed: 2019-09-24
- Published: 2022-01-20
- Earliest claimed: 2018-09-24
- Assignees: Takeda Phaarmaceutical Company Limited
- Applicants: Takeda Phaarmaceutical Company Limited
- Inventors: Shiro TAKEKAWA; Tomoko MORIMOTO; Minoru MARUYAMA; Hiroaki NAGAI; Akira TANAKA; Hisanori MATSUI; Atsuko OBINATA; Derek Cecil COLE; Mack FLINSPACH; Nick SCORAH; Abhijit Suresh BHAT
- Web page: https://patentgrep.com/patent/US20220016215A1

## CPC

- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- C07K 14/605: Glucagons
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides GIF receptor agonist peptide compounds having an activating action on GIF receptors and use of the GIF receptor agonist peptide as a medicament for the treatment and/or prevention of emesis. Specifically, a GIF receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are N provided. Formula (I) P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-P2, wherein each symbol is as defined herein, with the proviso that the GIF receptor agonist peptide is not native human GIF having an amino acid sequence as set forth in SEQ ID NO: 1.

## Claims

### Claim 1

A method for treating emesis in a subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide, or a salt thereof, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as set forth in SEQ ID NO: 1.

### Claim 2

A method for treating emesis in a subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide, or a salt thereof, with the proviso that the peptide does not have an amino acid sequence as set forth in any one of SEQ ID NOs: 4 to 569 disclosed in PCT Application No. PCT/JP2018/013540.

### Claim 3

A method for treating emesis in a subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide, or a salt thereof, wherein the GIP receptor agonist peptide has at least 80% sequence identity to amino acid sequence of the native human GIP peptide having an amino acid sequence as set forth in SEQ ID NO: 1, with the proviso that the peptide does not have an amino sequence as set forth in SEQ ID NO: 1.

### Claim 4

A method for treating emesis in a subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide having 29 or 30 amino acids, or a salt thereof.

### Claim 5

A method for treating emesis in a subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide, or a salt thereof, wherein the GIP receptor agonist peptide has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, or at least 97%, sequence identity to amino acid sequence of the native human GIP peptide having an amino acid sequence as set forth in SEQ ID NO: 1, with the proviso that the peptide does not have an amino sequence as set forth in SEQ ID NO: 1.

### Claim 6

A method for treating emesis in a subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide having 29 or 30 amino acids, or a salt thereof, wherein the GIP receptor agonist peptide has at least 80% sequence identity to amino acid sequence 1-29 or 1-30 of the native human GIP peptide having an amino acid sequence as set forth in SEQ ID NO: 1.

### Claim 7

A method for treating emesis in a subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide having 29 or 30 amino acids, or a salt thereof, wherein the GIP receptor agonist peptide has at least 80% sequence identity to amino acid sequence 1-29 or 1-30 of the native human GIP peptide having an amino acid sequence as set forth in SEQ ID NO: 1, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as set forth in any 29 or 30 amino acid peptide provided in SEQ ID NOs: 4 to 569 disclosed in PCT Application No. PCT/JP2018/013540.

### Claim 8

A method for treating emesis in a subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide, or a salt thereof, said peptide having the formula (I): P′-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A 18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-A43-P2,
wherein
P1 represents a group represented by formula
—RA1,
—CO—RA1,
—CO—ORA1,
—CO—CORA1,
—SO—RA1,
—SO2—RA1,
—SO2—ORA1,
—CO—NRA2RA3,
—SO2—NRA2RA3,
—C(═NRA1)—NRA2RA3, or
is absent,
wherein RA1, RA2, and RA3 each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group;
P2 represents —NH2 or —OH;
A1 represents Tyr, Phe, D-Tyr, mono-halo-Phe, bis-halo-Phe, mono-halo-Tyr, bis-halo-Tyr, mono-halo-D-Phe, bis-halo-D-Phe, mono-halo-D-Tyr, bis-halo-D-Tyr, or des-amino-Phe, or des-amino-Tyr;
A2 represents Ala, Aib, D-Ala, Gly, Ser, or Sar;
A3 represents Glu or Pro;
A4 represents Gly, or Ser;
A5 represents Thr, D-Iva, Glu, Iva, or Ser;
A6 represents Phe, Iva, Val, Ala, Aib, Cha, or α-methyl-Leu;
A7 represents Ile, Lys, Ala, Aib, Cha, D-Leu, Ile, Thr, Arg, or Val;
A8 represents Ser, Ala, ψ, or Aib;
A9 represents Asp, Leu, ψ, Phe, Glu, or Gln;
A10 represents Tyr, Leu, Ser, Cha, or ψ;
A11 represents Ser, Aib, A5c, A6c, D-Iva, or Iva;
A12 represents Ile, Lys, Glu, Asp, Ala, Aib, Lys-Ac, Ser, α-methyl-Phe, or ψ;
A13 represents Ala, Aib, Tyr, D-Iva, ψ, Gln, Leu, Glu, or Iva;
A14 represents Met, Nle, α-methyl-Leu, Leu, or ψ;
A15 represents Asp, Glu, Lys, Ser, Tyr, ψ, or Asn;
A16 represents Lys, Ala, Ser, Glu, Arg, Aib, Lys-Ac, or ψ;
A17 represents Ile, Lys, Arg, Aib, Gln, Glu, Lys-Ac, or ψ;
A18 represents His, Arg, Ala, Aib, D-Iva, Phe, Iva, Leu, Ser, Trp, or ψ;
A19 represents Gln, Lys, Glu, Ala, Val, Ser, Aib, Arg, or ψ;
A20 represents Gln, Lys, Ala, His, Arg, Aib, Asp, Gly, or ψ;
A21 represents Asp, Leu, Asn, Asp, Glu, Ala, Leu, Ser, Aib, or ψ;
A22 represents Phe, α-methyl-Phe, Naphthyl-Ala, Asn, Ala, Trp, or ψ;
A23 represents Val, Ile, or ψ;
A24 represents Asn, Asp, Glu, Ala, Aib, Gln, Glu, Lys, Lys-Ac, Leu, Nle, Arg, Ser, or ψ;
A25 represents Trp, Tyr, Glu, Phe, Arg, α-methyl-Phe, or ψ;
A26 represents Leu, Aib, Iva, Leu, Nle, or ψ;
A27 represents Leu, Glu, Ser, Lys, Val, Ile, Nle, or ψ;
A28 represents Ala, Ser, Arg, Leu, Met, Lys, Lys-Ac, Aib, or ψ;
A29 represents Gln, Gly, Ala, Thr, Ser, Lys, Aib, ψ, or deletion;
A30 represents Lys, Arg, Gly, Pro, Glu, Lys-Ac, ψ, or deletion;
A31 represents Phe, Pro, Gly, ψ, or deletion;
A32 represents Lys, Ser, Gly, ψ, or deletion;
A33 represents Lys, Ser, Gly, Ile, Ser, ψ, or deletion;
A34 represents Asn, Ala, Gly, Gln, ψ, or deletion;
A35 represents Asp, Ala, Ser, Pro, Glu, ψ, or deletion;
A36 represents Trp, Pro, Gly, ψ, or deletion;
A37 represents Lys, Pro, Gly, ψ, or deletion;
A38 represents His, Pro, Gly, Ser, ψ, or deletion;
A39 represents Asn, Ser, Gly, Asn, Lys, Gln, ψ, or deletion;
A40 represents Ile, Arg, Glu, Lys, Ser, Lys-Ac, Arg, ψ, or deletion;
A41 represents Ile, Thr, Gly, ψ, or deletion;
A42 represents Gln, Gly, ψ, or deletion;
A43 represents ψ, or deletion;
wherein ψ is a residue independently selected from Lys, Arg, Orn, and Cys and wherein the side chain of said residue is substituted, with the proviso that the GIP receptor agonist peptide is not native human GIP having an amino acid sequence as set forth in SEQ ID NO: 1.

### Claim 9

A method for treating emesis in a subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide, or a salt thereof, said peptide having the formula (II): P1-A1-A2-A3-Gly-Thr-A6-A7-Ser-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-Trp-Leu-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-A43-P2,
wherein
P1 represents a group represented by formula
—RA1,
—CO—RA1,
—CO—ORA1,
—CO—CORA1,
—SO—RA1,
—SO2—RA1,
—SO2—ORA1,
—CO—NRA2RA3,
—SO2—NRA2RA3,
—C(═NRA1)—NRA2RA3, or is absent;
wherein RA1, RA2, and RA3 each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group;
P2 represents —NH2 or —OH;
A1 represents Tyr, Phe, D-Tyr, mono-halo-Phe, bis-halo-Phe, mono-halo-Tyr, bis-halo-Tyr, mono-halo-D-Phe, bis-halo-D-Phe, mono-halo-D-Tyr, bis-halo-D-Tyr, des-amino-Phe, or des-amino-Tyr;
A2 represents Ala, Aib, D-Ala, Gly, Ser, or Sar;
A3 represents Glu, or Pro;
A6 represents Phe, Iva, or Val;
A7 represents Ile, Lys, Thr, or Val;
A9 represents Asp, Leu, or Phe;
A10 represents Tyr, or ψ;
A11 represents Ser, A5c, Leu, Aib, or Cha;
A12 represents Ile, Lys, Glu, Asp, or ψ;
A13 represents Ala, Aib, Tyr, D-Iva, Gln, Leu, or Glu;
A14 represents Met, Nle, Leu, or ψ;
A15 represents Asp, Glu, Lys, Ser, or Tyr;
A16 represents Lys, Ala, Ser, Glu, Arg, or ψ;
All represents Ile, Lys, Arg, Aib, Gln, Ile, Glu, or ψ;
A18 represents His, Ala, or ψ;
A19 represents Gln, Lys, Glu, Ala, Val, Ser, or ψ;
A20 represents Gln, Lys, Ala, His, Arg, Aib, or ψ;
A21 represents Asp, Leu, Asn, Glu, Ala, Leu, Ser, or ψ;
A22 represents Phe, or ψ;
A23 represents Val, Ile, or ψ;
A24 represents Asn, Asp, Glu, Ala, Gln, Arg, Asn, Asp, Lys, Lys-Ac, or ψ;
A25 represents Trp, or ψ;
A26 represents Leu, Aib, Iva, or ψ;
A27 represents Leu, Glu, Ser, Lys, Val, Ile, or ψ;
A28 represents Ala, Ser, Arg, Leu, Met, Lys, Lys-Ac, or ψ;
A29 represents Gln, Gly, Ala, Thr, Ser, Lys, Aib, ψ, or deletion;
A30 represents Lys, Arg, Gly, Pro, ψ, or deletion;
A31 represents Phe, Pro, Gly, ψ, or deletion;
A32 represents Lys, Ser, Gly, ψ, or deletion;
A33 represents Lys, Ser, Gly, ψ, or deletion;
A34 represents Lys, Gly, Ala, Gln, ψ, or deletion;
A35 represents Asp, Ala, Ser, Pro, Glu, ψ, or deletion;
A36 represents Trp, Pro, Gly, ψ, or deletion;
A37 represents Lys, Pro, Gly, ψ, or deletion;
A38 represents His, Pro, Ser, Gly, ψ, or deletion;
A39 represents Asn, Lys, Gly, Gln, Ser, ψ, or deletion;
A40 represents Ile, Arg, Lys, Ser, ψ, or deletion;
A41 represents Ile, Thr, ψ, or deletion;
A42 represents Gln, Gly, ψ, or deletion;
A43 represents ψ, or deletion;
wherein ψ is a residue independently selected from Lys, Arg, Orn, and Cys and wherein the side chain of said residue is substituted, and with the proviso that the GIP receptor agonist peptide is not a peptide having an amino acid sequence of SEQ ID NOs: 4 to 569 disclosed in PCT Application No. PCT/JP2018/013540, and wherein, one or two amino acids selected from A8 to A42 optionally represent Lys(R), and R represents a substituent group, or a salt thereof.

### Claim 10

A method for treating emesis in a subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide, or a salt thereof, said peptide having at least 80% sequence identity to a peptide having the formula (III): P1-A1-A2-A3-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-A11-Ile-A13-A14-A15-A16-A17-His-Gln-A20-Asp-Phe-Val-A24-Trp-Leu-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-A43-P2,
wherein
P1 represents a group represented by formula
—RA1,
—CO—RA1,
—CO—ORA1,
—CO—CORA1,
—SO—RA1,
—SO2—RA1,
—SO2—ORA1,
—CO—NRA2RA3,
—SO2—NRA2RA3,
—C(═NRA1)—NRA2RA3, or is absent;
wherein RA1, RA2, and RA3 each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group;
P2 represents —NH2 or —OH;
A1 represents Tyr, Phe, di-Br-Tyr;
A2 represents Ala, or Aib;
A3 represents Glu, or Pro;
A11 represents Ser, A5c, or A6c;
A13 represents Ala, or Aib;
A14 represents Met, Leu or Nle;
A15 represents Asp or Glu;
A16 represents Lys, Ala, or Lys(R);
A17 represents Ile, or Lys(R);
A20 represents Gln, or Lys(R);
A24 represents Asn, or Asp;
A27 represents Leu or Lys(R);
A28 represents Ala or Lys(R);
A29 represents Gln or Lys(R);
A30 represents Lys, Pro, or Lys(R);
A31 represents Phe, Pro, or deletion;
A32 represents Lys, Ser, or deletion;
A33 represents Lys, Ser, or deletion;
A34 represents Asn, Ala, Gly, or deletion;
A35 represents Asp, Pro, Ala, or deletion;
A36 represents Trp, Pro, or deletion;
A37 represents Lys, Pro, Lys(R), or deletion;
A38 represents His, Pro, Ser, or deletion;
A39 represents Asn, Ser, or deletion;
A40 represents Ile, Lys(R), or deletion;
A41 represents Ile, Thr, or deletion;
A42 represents Gln, or deletion;
A43 represents ψ, or deletion;
wherein Lys(R) is a Lys residue and (R) represents a substitutent group, or salt thereof, with the proviso that the GIP receptor agonist peptide is not a peptide having an amino acid sequence of SEQ ID NOs: 4 to 569 disclosed in PCT Application No. PCT/JP2018/013540, and wherein, one or two amino acids selected from A8 to A42 optionally represent Lys(R), and the (R) in Lys(R) represents a substituent group, or a salt thereof.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the GIP receptor agonist peptide has at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or at least 100% sequence identity to a GIP receptor agonist peptide having an amino acid sequence of SEQ ID NOs: 4-37.

### Claim 12

A method for treating emesis in a subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide, or a salt thereof, said peptide having at least 80% sequence identity to a peptide having the formula (IV): P1-A1-A2-A3-Gly-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-A43-P2,
wherein
P1 represents a group represented by formula
—RA1,
—CO—RA1,
—CO—ORA1,
—CO—CORA1,
—SO—RA1,
—SO2—RA1,
—SO2—ORA1,
—CO—NRA2RA3,
—SO2—NRA2RA3,
—C(═NRA1)—NRA2RA3, or is absent,
wherein RA1, RA2, and RA3 each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group;
P2 represents —NH2 or —OH;
A1 represents Tyr, D-Tyr, Phe, or 3,5 di-Br-Tyr;
A2 represents Aib, Ala, or D-Ala;
A3 represents Glu, or Pro;
A5 represents Thr, or Glu;
A6 represents Iva, Phe, or Val;
A7 represents Ile, Lys, Thr, or Val;
A8 represents Ser, or Lys(R);
A9 represents Asp, Leu, Lys(R), or Phe;
A10 represents Tyr, or Lys(R);
A11 represents Aib, A5c, A6c, or Ser;
A12 represents Ile, Glu, or Lys(R);
A13 represents Aib, Ala, Gln, Glu, Leu, Lys(R), Tyr, or D-Iva;
A14 represents Leu, Met, Lys(R), or Nle;
A15 represents Asp, Glu, Lys, Lys(R), Ser, or Tyr;
A16 represents Arg, Ala, Lys(R), or Lys;
A17 represents Aib, Glu, Lys(R), Gln, or Ile;
A18 represents Ala, Lys(R), or His;
A19 represents Gln, Lys(R), Glu, Val, Ala, or Ser;
A20 represents Aib, Lys(R), Arg, Ala, or Gln;
A21 represents Asn, Asp, Ala, Glu, Lys(R), Leu, Aib, or Ser;
A22 represents Phe, Lys(R), Naphthyl-Ala, or αMePhe;
A23 represents Ile, Lys(R), or Val;
A24 represents Arg, Asn, Ala, Gln, Glu, Asp, Lys, or Lys(R);
A25 represents Trp, Lys(R), or αMePhe;
A26 represents Aib, Lys(R), Iva, or Leu;
A27 represents Leu, Lys(R), Val, or Ile;
A28 represents Ala, Arg, Lys, or Lys(R);
A29 represents Gln, Aib, or Gly;
A30 represents Arg, Lys, Pro, Gly, Lys(R), or a deletion;
A31 represents Gly, Pro, or a deletion;
A32 represents Lys, Ser, or a deletion;
A33 represents Lys, Ser, or a deletion;
A34 represents Asn, Gly, Ala, Gln, or a deletion;
A35 represents Asp, Glu, Pro, Ala, or a deletion;
A36 represents Trp, Pro, or a deletion;
A37 represents Lys, Pro, Lys(R), or a deletion;
A38 represents His, Ser, Pro or a deletion;
A39 represents Asn, Gln, Lys, Ser, or a deletion;
A40 represents Arg, Glu, Ile, Lys, Lys(R), or a deletion;
A41 represents Ile, Thr, or a deletion;
A42 represents Gln or a deletion;
with the proviso that if A14 is Leu or Lys(R), then the GIP receptor agonist peptide is at least 40 amino acids in length, and A40 is not Arg, Lys or Glu, and wherein any one or two amino acids selected from A8 to A42 optionally represent Lys(R), and the (R) in Lys(R) represents a substituent group.

### Claim 13

A method for treating emesis in a subject, the method consisting of administering a therapeutically effective dose of a monotherapy, the monotherapy consisting essentially of a GIP receptor agonist peptide, or a salt thereof, said peptide having at least 80% sequence identity to a peptide having the formula (IV): P1-A1-A2-A3-Gly-A5-A6-A7-A8-A9-A 10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-A43-P2,
wherein
P1 represents a group represented by formula
—RA1,
—CO—RA1,
—CO—ORA1,
—CO—CORA1,
—SO—RA1,
—SO2—RA1,
—SO2—ORA1,
—CO—NRA2RA3,
—SO2—NRA2RA3,
—C(═NRA1)—NRA2RA3, or is absent,
wherein RA1, RA2, and RA3 each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group;
P2 represents —NH2 or —OH;
A1 represents Tyr, D-Tyr, Phe, or 3,5 di-Br-Tyr;
A2 represents Aib, Ala, or D-Ala;
A3 represents Glu, or Pro;
A5 represents Thr, or Glu;
A6 represents Iva, Phe, or Val;
A7 represents Ile, Lys, Thr, or Val;
A8 represents Ser, or Lys(R);
A9 represents Asp, Leu, Lys(R), or Phe;
A10 represents Tyr, or Lys(R);
A11 represents Aib, A5c, A6c, or Ser;
A12 represents Ile, Glu, or Lys(R);
A13 represents Aib, Ala, Gln, Glu, Leu, Lys(R), Tyr, or D-Iva;
A14 represents Leu, Met, Lys(R), or Nle;
A15 represents Asp, Glu, Lys, Lys(R), Ser, or Tyr;
A16 represents Arg, Ala, Lys(R), or Lys;
A17 represents Aib, Glu, Lys(R), Gln, or Ile;
A18 represents Ala, Lys(R), or His;
A19 represents Gln, Lys(R), Glu, Val, Ala, or Ser;
A20 represents Aib, Lys(R), Arg, Ala, or Gln;
A21 represents Asn, Asp, Ala, Glu, Lys(R), Leu, Aib, or Ser;
A22 represents Phe, Lys(R), Naphthyl-Ala, or αMePhe;
A23 represents Ile, Lys(R), or Val;
A24 represents Arg, Asn, Ala, Gln, Glu, Asp, Lys, or Lys(R);
A25 represents Trp, Lys(R), or αMePhe;
A26 represents Aib, Lys(R), Iva, or Leu;
A27 represents Leu, Lys(R), Val, or Ile;
A28 represents Ala, Arg, Lys, or Lys(R);
A29 represents Gln, Aib, or Gly;
A30 represents Arg, Lys, Pro, Gly, Lys(R), or a deletion;
A31 represents Gly, Pro, or a deletion;
A32 represents Lys, Ser, or a deletion;
A33 represents Lys, Ser, or a deletion;
A34 represents Asn, Gly, Ala, Gln, or a deletion;
A35 represents Asp, Glu, Pro, Ala, or a deletion;
A36 represents Trp, Pro, or a deletion;
A37 represents Lys, Pro, Lys(R), or a deletion;
A38 represents His, Ser, Pro or a deletion;
A39 represents Asn, Gln, Lys, Ser, or a deletion;
A40 represents Arg, Glu, Ile, Lys, Lys(R), or a deletion;
A41 represents Ile, Thr, or a deletion;
A42 represents Gln or a deletion;
with the proviso that if A14 is Leu or Lys(R), then the GIP receptor agonist peptide is at least 40 amino acids in length, and A40 is not Arg, Lys or Glu, and wherein any one or two amino acids selected from A8 to A42 optionally represent Lys(R), and the (R) in Lys(R) represents a substituent group.

### Claim 14

A method for treating emesis in a subject, the method consisting of administering a therapeutically effective dose of a monotherapy, the monotherapy consisting essentially of a GIP receptor agonist peptide, or a salt thereof, said peptide having at least 80% sequence identity to a peptide having the formula (IV): P1-A1-A2-A3-Gly-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-A43-P2,
wherein
P1 represents a group represented by formula
—RA1,
—CO—RA1,
—CO—ORA1,
—CO—CORA1,
—SO—RA1,
—SO2—RA1,
—SO2—ORA1,
—CO—NRA2RA3,
—SO2—NRA2RA3,
—C(═NRA1)—NRA2RA3, or is absent,
wherein RA1, RA2, and RA3 each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group;
P2 represents —NH2 or —OH;
A1 represents Tyr, D-Tyr, Phe, or 3,5 di-Br-Tyr;
A2 represents Aib, Ala, or D-Ala;
A3 represents Glu, or Pro;
A5 represents Thr, or Glu;
A6 represents Iva, Phe, or Val;
A7 represents Ile, Lys, Thr, or Val;
A8 represents Ser, or Lys(R);
A9 represents Asp, Leu, Lys(R), or Phe;
A10 represents Tyr, or Lys(R);
A11 represents Aib, A5c, A6c, or Ser;
A12 represents Ile, Glu, or Lys(R);
A13 represents Aib, Ala, Gln, Glu, Leu, Lys(R), Tyr, or D-Iva;
A14 represents Leu, Met, Lys(R), or Nle;
A15 represents Asp, Glu, Lys, Lys(R), Ser, or Tyr;
A16 represents Arg, Ala, Lys(R), or Lys;
A17 represents Aib, Glu, Lys(R), Gln, or Ile;
A18 represents Ala, Lys(R), or His;
A19 represents Gln, Lys(R), Glu, Val, Ala, or Ser;
A20 represents Aib, Lys(R), Arg, Ala, or Gln;
A21 represents Asn, Asp, Ala, Glu, Lys(R), Leu, Aib, or Ser;
A22 represents Phe, Lys(R), Naphthyl-Ala, or αMePhe;
A23 represents Ile, Lys(R), or Val;
A24 represents Arg, Asn, Ala, Gln, Glu, Asp, Lys, or Lys(R);
A25 represents Trp, Lys(R), or αMePhe;
A26 represents Aib, Lys(R), Iva, or Leu;
A27 represents Leu, Lys(R), Val, or Ile;
A28 represents Ala, Arg, Lys, or Lys(R);
A29 represents Gln, Aib, or Gly;
A30 represents Arg, Lys, Pro, Gly, Lys(R), or a deletion;
A31 represents Gly, Pro, or a deletion;
A32 represents Lys, Ser, or a deletion;
A33 represents Lys, Ser, or a deletion;
A34 represents Asn, Gly, Ala, Gln, or a deletion;
A35 represents Asp, Glu, Pro, Ala, or a deletion;
A36 represents Trp, Pro, or a deletion;
A37 represents Lys, Pro, Lys(R), or a deletion;
A38 represents His, Ser, Pro or a deletion;
A39 represents Asn, Gln, Lys, Ser, or a deletion;
A40 represents Arg, Glu, Ile, Lys, Lys(R), or a deletion;
A41 represents Ile, Thr, or a deletion;
A42 represents Gln or a deletion;
with the proviso that if A14 is Leu or Lys(R), then the GIP receptor agonist peptide is at least 40 amino acids in length, and A40 is not Arg, Lys or Glu, and wherein any one or two amino acids selected from A8 to A42 optionally represent Lys(R), and the (R) in Lys(R) represents a substituent group.

### Claim 15

A method for treating emesis in a subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide, or a salt thereof, having an amino acid sequence of formula (V): P1-Tyr-A2-A3-Gly-Thr-Phr-A7-Ser-Asp-A10-Ser-A12-Ala-A14-A15-A16-A 17-A18-A 19-A20-A21-Phe-A23-A24-A25-Leu-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-P2,
wherein
P1 represents a group represented by formula
—RA1,
—CO—RA1,
—CO—ORA1,
—CO—CORA1,
—SO—RA1,
—SO2—RA1,
—SO2—ORA1,
—CO—NRA2RA3,
—SO2—NRA2RA3,
—C(═NRA1)—NRA2RA3, or is absent,
wherein RA1, RA2, and RA3 each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group;
P2 represents —NH2 or —OH;
A2 represents Aib, Ala, Gly, Ser, D-Ala, or N-methyl-Ser;
A3 represents Glu, Asp, or Gln;
A7 represents Ile, or Ser, Thr;
A10 represents Tyr, Leu, or Ser;
A12 represents Ile, Lys, or ψ;
A14 represents Ile, Leu, or Met;
A15 represents Asp, or Glu;
A16 represents Lys, Ser, Glu or w;
A17 represents Ile, Lys, Gln, or ψ;
A18 represents Ala, Arg, or His;
A19 represents Gln, Ala, Lys, or Glu;
A20 represents Gln, Arg, or Lys, His or Ala;
A21 represents Asp, or Ala;
A23 represents Val, or Ile;
A24 represents Asn, Gln, or Asp;
A25 represents Trp, or Thr;
A27 represents Leu, Glu, Ser, Lys, or Val;
A28 represents Ala, Ser or Arg;
A29 represents Gln, Aib, Gly, Ala, Thr, Ser or Lys;
A30 represents Lys Gly or ψ;
A31 represents Gly, Pro Gly-OH, or a deletion;
A32 represents Lys, Ser, or a deletion;
A33 represents Lys, Ser, or a deletion;
A34 represents Asn, Gly, or a deletion;
A35 represents Asp, Ala, or a deletion;
A36 represents Trp, Pro, or a deletion;
A37 represents Lys, Pro, or a deletion;
A38 represents His, Pro, or a deletion;
A39 represents Asn, Ser, or a deletion;
A40 represents Ile, or a deletion;
A41 represents Thr, or a deletion;
A42 represents Gln, or a deletion;
wherein ψ is a residue independently selected from Lys, Arg, Orn, and Cys and wherein the side chain of said residue is substituted, with the proviso that the GIP receptor agonist peptide is not native human GIP having an amino acid sequence as set forth in SEQ ID NO: 1.

### Claim 16

A method for treating emesis in a subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide, or a salt thereof, having an amino acid sequence of formula (VI): P1-Tyr-A2-Glu-Gly-Thr-Phr-A7-Ser-Asp-Thr-Ser-Ile-A13-A14-Asp-Lys-Ile-A18-Gln-A20-A21-A22-Val-A24-Trp-Leu-A27-Ala-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-P2,
wherein
P1 represents a group represented by formula
RA1,
—CO—RA1,
—CO—ORA1,
—CO—CORA1,
—SO—RA1,
—SO2—RA1,
—SO2—ORA1,
—CO—NRA2RA3,
—SO2—NRA2RA3,
—C(═NRA1)—NRA2RA3, or is absent,
wherein RA1, RA2, and RA3 each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group;
P2 represents —NH2 or —OH;
A2 represents Aib or Ala;
A7 represents Ile, or s, Thr;
A13 represents Aib, or Ala;
A14 represents Leu, or Met;
A18 represents Ala, or His;
A20 represents Gln, Arg, or ψ;
A21 represents Asp, or Ala;
A22 represents Phe, Naphthyl-Ala, or αMePhe;
A24 represents Asn, or Gln;
A27 represents Leu or Ile;
A29 represents Gln, Aib, or Gly;
A30 represents Lys or Gly;
A31 represents Gly or Pro;
A32 represents Lys, or Ser;
A33 represents Lys, or Ser;
A34 represents Asn, Gly, or Gln;
A35 represents Asp, Glu, or Ala;
A36 represents Trp, or Pro;
A37 represents Lys, or Pro;
A38 represents His, or Pro;
A39 represents Asn, Gln, or Ser;
A40 represents Ile, or a deletion;
A41 represents Ile, Thr, or a deletion;
A42 represents Gln, or a deletion;
wherein ψ is a residue independently selected from Lys, Arg, Orn, and Cys and wherein the side chain of said residue is substituted, with the proviso that the GIP receptor agonist peptide is not native human GIP having an amino acid sequence as set forth in SEQ ID NO: 1.

### Claim 17

A method for treating emesis in a subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide, or a salt thereof, having an amino acid sequence of formula (VII): P1-Tyr-A2-Glu-Gly-Thr-Phr-A7-Ser-Asp-Thr-Ser-A12-A13-A14-Asp-A16-A17-A18-Gln-A20-A21-Phe-Val-A24-Trp-A26-A27-Ala-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-P2,
wherein
P1 represents a group represented by formula
—RA1,
—CO—RA1,
—CO—ORA1,
—CO—CORA1,
—SO—RA1,
—SO2—RA1,
—SO2—ORA1,
—CO—NRA2RA3,
—SO2—NRA2RA3,
—C(═NRA1)—NRA2RA3, or is absent,
wherein RA1, RA2, and RA3 each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group;
P2 represents —NH2 or —OH;
A2 represents Aib or Ala;
A7 represents Ile, Leu, or Thr;
A12 represents Ile or Leu;
A 13 represents Aib, or Ala;
A14 represents Leu, Met or ψ;
A16 represents Lys or Arg;
A17 represents Ile or Aib;
A18 represents Ala, His, or ψ;
A20 represents Gln, or Aib;
A21 represents Asp, Ala, Asn or ψ;
A24 represents Asn, Glu, or Gln;
A26 represents Leu or Ile;
A27 represents Leu or Ile;
A29 represents Gln or ψ;
A30 represents Lys, Arg, ψ, Ser or Gln;
A31 represents Gly, Pro, or a deletion;
A32 represents Ser, or a deletion;
A33 represents Ser, or a deletion;
A34 represents Gly, or a deletion;
A35 represents Ala, or a deletion;
A36 represents Pro, or a deletion;
A37 represents Pro, or a deletion;
A38 represents Pro, or a deletion;
A39 represents Ser, or a deletion;
wherein ψ is a residue independently selected from Lys, Arg, Orn, and Cys and wherein the side chain of said residue is substituted, with the proviso that the GIP receptor agonist peptide is not native human GIP having an amino acid sequence as set forth in SEQ ID NO: 1.
GIP receptor agonistGIP receptor agonistGIP receptor agonistGIP receptor agonist.

### Claim 18

A method for treating emesis in a non-type 2 diabetes mellitus subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide, or a salt thereof, said GIP receptor agonist peptide having an amino acid sequence of formula (I): P′-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A 18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-A43-P2,
wherein
P1 represents a group represented by formula
—RA1,
—CO—RA1,
—CO—ORA1,
—CO—CORA1,
—SO—RA1,
—SO2—RA1,
—SO2—ORA1,
—CO—NRA2RA3,
—SO2—NRA2RA3,
—C(═NRA1)—NRA2RA3, or is absent,
wherein RA1, RA2, and RA3 each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group;
P2 represents —NH2 or —OH;
A1 represents Tyr, Phe, D-Tyr, mono-halo-Phe, bis-halo-Phe, mono-halo-Tyr, bis-halo-Tyr, mono-halo-D-Phe, bis-halo-D-Phe, mono-halo-D-Tyr, bis-halo-D-Tyr, des-amino-Phe, or des-amino-Tyr;
A2 represents Ala, Aib, D-Ala, Gly, Ser, or Sar;
A3 represents Glu, or Pro;
A4 represents Gly, or Ser;
A5 represents Thr, D-Iva, Glu, Iva, or Ser;
A6 represents Phe, Iva, Val, Ala, Aib, Cha, or α-methyl-Leu;
A7 represents Ile, Lys, Ala, Aib, Thr, Cha, D-Leu, Ile, Arg, or Val;
A8 represents Ser, Ala, ψ, or Aib;
A9 represents Asp, Leu, ψ, Phe, Glu, or Gln;
A10 represents Tyr, Leu, Ser, Cha, or ψ;
A11 represents Ser, Aib, A5c, A6c, D-Iva, or Iva;
A12 represents Ile, Lys, Glu, Asp, Ala, Aib, Lys-Ac, Ser, α-methyl-Phe, or ψ;
A 13 represents Ala, Aib, Tyr, D-Iva, ψ, Gln, Leu, Glu, or Iva;
A14 represents Met, Nle, Leu, α-methyl-Leu, or ψ;
A15 represents Asp, Glu, Lys, Ser, Tyr, ψ, or Asn;
A16 represents Lys, Ala, Ser, Glu, Arg, Aib, Lys-Ac, or ψ;
A17 represents Ile, Lys, Arg, Aib, Gln, Glu, Lys-Ac, or ψ;
A18 represents His, Arg, Ala, Aib, D-Iva, Phe, Iva, Leu, Ser, Trp, or ψ;
A19 represents Gln, Lys, Glu, Ala, Val, Ser, Aib, Arg, or ψ;
A20 represents Gln, Lys, Ala, His, Arg, Aib, Asp, Gly, or ψ;
A21 represents Asp, Leu, Asn, Asp, Glu, Ala, Leu, Ser, Aib, or ψ;
A22 represents Phe, α-methyl-Phe, Naphthyl-Ala, Asn, Ala, Trp, or ψ;
A23 represents Val, Ile, or ψ;
A24 represents Asn, Asp, Glu, Ala, Aib, Gln, Glu, Lys, Lys-Ac, Leu, Nle, Arg, Ser, or ψ;
A25 represents Trp, Tyr, Glu, Phe, Arg, α-methyl-Phe, or ψ;
A26 represents Leu, Aib, Iva, Leu, Nle, or ψ;
A27 represents Leu, Glu, Ser, Lys, Val, Ile, Nle, or ψ;
A28 represents Ala, Ser, Arg, Leu, Met, Lys, Lys-Ac, Aib, or ψ;
A29 represents Gln, Gly, Ala, Thr, Ser, Lys, Aib, ψ, or a deletion;
A30 represents Lys, Arg, Pro, Gly, Glu, Lys-Ac, ψ, or a deletion;
A31 represents Phe, Pro, Gly, ψ, or a deletion;
A32 represents Lys, Ser, Gly, ψ, or a deletion;
A33 represents Lys, Ser, Gly, Ile, Ser, ψ, or a deletion;
A34 represents Asn, Gly, Ala, Gln, ψ, or a deletion;
A35 represents Asp, Ala, Pro, Ser, Glu, ψ, or a deletion;
A36 represents Trp, Pro, Gly, ψ, or a deletion;
A37 represents Lys, Pro, Gly, ψ, or a deletion;
A38 represents His, Pro, Ser, Gly, ψ, or a deletion;
A39 represents Asn, Ser, Gly, Asn, Lys, Gln, ψ, or a deletion;
A40 represents Ile, Arg, Glu, Lys, Ser, Lys-Ac, Arg, ψ, or a deletion;
A41 represents Ile, Thr, Gly, ψ, or a deletion;
A42 represents Gln, Gly, ψ, or a deletion;
A43 represents ψ, or a deletion;
wherein ψ is a residue independently selected from Lys, Arg, Orn, and Cys and wherein the side chain of said residue is substituted, with the proviso that the GIP receptor agonist peptide is not native human GIP having an amino acid sequence as set forth in SEQ ID NO: 1.

### Claim 19

A method for treating emesis in a non-type 2 diabetes mellitus subject, the method comprising administering a therapeutically effective amount of a GIP receptor agonist peptide, or a salt thereof, said GIP receptor agonist peptide having an amino acid sequence of formula (IV): P1-A1-A2-A3-Gly-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-A43-P2,
wherein
P1 represents a group represented by formula
—RA1,
—CO—RA1,
—CO—ORA1,
—CO—CORA1,
—SO—RA1,
—SO2—RA1,
—SO2—ORA1,
—CO—NRA2RA3,
—SO2—NRA2RA3,
—C(═NRA1)—NRA2RA3, or is absent,
wherein RA1, RA2, and RA3 each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group;
P2 represents —NH2 or —OH;
A1 represents Tyr, D-Tyr, Phe, or 3,5 di-Br-Tyr;
A2 represents Aib, Ala, or D-Ala;
A3 represents Glu, or Pro;
A5 represents Thr, or Glu;
A6 represents Iva, Phe, or Val;
A7 represents Ile, Lys, Thr, or Val;
A8 represents Ser, or Lys(R);
A9 represents Asp, Leu, Lys(R), or Phe;
A10 represents Tyr, or Lys(R);
A11 represents Aib, A5c, A6c, or Ser;
A12 represents Ile, Glu, or Lys(R);
A13 represents Aib, Ala, Gln, Glu, Leu, Lys(R), Tyr, or D-Iva;
A14 represents Leu, Met, Lys(R), or Nle;
A15 represents Asp, Glu, Lys, Lys(R), Ser, or Tyr;
A16 represents Arg, Ala, Lys(R), or Lys;
A17 represents Aib, Glu, Lys(R), Gln, or Ile;
A18 represents Ala, Lys(R), or His;
A19 represents Gln, Lys(R), Glu, Val, Ala, or Ser;
A20 represents Aib, Lys(R), Arg, Ala, or Gln;
A21 represents Asn, Asp, Ala, Glu, Lys(R), Leu, Aib, or Ser;
A22 represents Phe, Lys(R), Naphthyl-Ala, or αMePhe;
A23 represents Ile, Lys(R), or Val;
A24 represents Arg, Asn, Ala, Gln, Glu, Asp, Lys, or Lys(R);
A25 represents Trp, Lys(R), or αMePhe;
A26 represents Aib, Lys(R), Iva, or Leu;
A27 represents Leu, Lys(R), Val, or Ile;
A28 represents Ala, Arg, Lys, or Lys(R);
A29 represents Gln, Aib, or Gly;
A30 represents Arg, Lys, Pro, Gly, Lys(R), or a deletion;
A31 represents Gly, Pro, or a deletion;
A32 represents Lys, Ser, or a deletion;
A33 represents Lys, Ser, or a deletion;
A34 represents Asn, Gly, Ala, Gln, or a deletion;
A35 represents Asp, Glu, Pro, Ala, or a deletion;
A36 represents Trp, Pro, or a deletion;
A37 represents Lys, Pro, Lys(R), or a deletion;
A38 represents His, Pro, Ser, or a deletion;
A39 represents Asn, Gln, Lys, Ser, or a deletion;
A40 represents Arg, Glu, Ile, Lys, Lys(R), or a deletion;
A41 represents Ile, Thr, or a deletion;
A42 represents Gln, or a deletion;
with the proviso that the GIP receptor agonist peptide is not a peptide having an amino acid sequence of SEQ ID NOs: 4 to 569 disclosed in PCT Application No. PCT/JP2018/013540, and wherein any one or two amino acids selected from A8 to A42 optionally represent Lys(R), and the (R) in Lys(R) represents a substituent group, or a salt thereof.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the (R) group in Lys(R) represents X-L-, L represents a bivalent linker comprising PEG and/or two or more amino acids, and X represents a substituent group, or a salt thereof.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the (R) group in Lys(R) represents X-L-, L represents a bond or a bivalent substituent group, and X represents an optionally substituted hydrocarbon group, or a salt thereof.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the (R) group in Lys(R) represents X-L-, L represents a bond or a bivalent substituent group, and X represents a C6-C20 monoacid, a C6-C20 diacid or an acetyl group, or a salt thereof.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: Ac-YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNIIQ-OH (SEQ ID NO: 4), or a salt thereof.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: Y(D-Ala)EGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDW(Lys(R))HNIIQ-NH2 (SEQ ID NO: 5), or a salt thereof.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAEGTFISDYSIAMD(Lys-(R)IHQQDFVNWLLAQKGKKNDWKHNIIQ-NH2 (SEQ ID NO: 6), or a salt thereof.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YD-AlaEGTFISDYSIAMDKIHQQDFVNWLLAQK-OH (SEQ ID NO: 7), or a salt thereof.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFISDYSIAMDKK(g-Glu-C16)HQQDFVNWLLAQKGKKNDWKHNIIQ-OH (SEQ ID NO: 8), or a salt thereof.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: FAibEGTFISDYX*IA(Nle)DKIHQQDFVNWLLAQKGKKNDWKHNITQ-OH (X* is 1-amino,1-cyclopentane carboxylic acid; SEQ ID NO: 12), wherein R represents a substituent group, or a salt thereof.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: (3,5-diBr-Tyr)AibEGTFISDYSIAib(Nle)DKIHQQDFVNWLLAQKGKKNDWKHNITQ-OH (SEQ ID NO: 11), wherein R represents a substituent group, or a salt thereof.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula:
(SEQ ID NO: 15)
YAPGTFISDYSIAMDKIHQQDFVNWLLAQIKPSSGAPPPS-NH2,
wherein R represents a substituent group, or a salt thereof.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: Y(D-Ala)EGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 14), wherein R represents a substituent group, or a salt thereof.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFTSDYSIYMEKEAV(Lys(R))EFIAWLVKG-OH (SEQ ID NO: 9), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula:
(SEQ ID NO: 10)
Ac-(D-Tyr)AEGTFISDYSIAMDAIHQQDFVNWLLAQ(LysR)-NH2,
wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFTSDYSIYLDKQAAAibEFVNWLLAGGPSSGAPPPS(Lys(R))—NH2 (SEQ ID NO: 13), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YD-AlaEGTFISDYSIAMD(Lys(R))IHQQDFVNWLLAQKGKKNDWKHNIIQ-NH2 (SEQ ID NO: 16), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula:
(SEQ ID NO: 17)
YD-AlaEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNIIQ-NH2.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFTSDYSIYMEKEAVREFIAWLVKGGPSSGAPPPS(Lys(R))—NH2 (SEQ ID NO: 18), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFTSDYSIAibLDKIAQRAFVQWLIAAibKGKKQEWKHQITQ(Lys(R))—NH2 (SEQ ID NO: 19), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFTSDYSIYLDKQAAAibEFVNWLLAGGPSSGAPPPS-(Lys(R))—NH2 (SEQ ID NO: 20), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFTSDYSIAibLDKIAQ(Lys(R))AFVQWLIAGGPSSGAPPPS-NH2 (SEQ ID NO: 21), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ(Lys(R))—OH (SEQ ID NO: 22), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFISDYSIELDK(Lys(R))AAQAFIEWLLAQGPSSGAPPPS-NH2 (SEQ ID NO: 23), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFISDYSIELDKIAAQDFIEWLLAGPSSGAPPPS(Lys(R))—NH2 (SEQ ID NO: 24), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFISDYS(Lys(R))ELDKIAQRAFIEWLLAQGPSSGAPPPS-NH2(SEQ ID NO: 25), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFISDYSIELEK(Lys(R))AQRAFVEWLLAQGPSSGAPPPS-NH2 (SEQ ID NO: 26), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFISDYSIALDKIHQQ(Lys(R))FVNWLLAQRG-OH (SEQ ID NO: 27), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFISDYSIALDKI(Lys(R))QQDFVNWLLAQRG-OH (SEQ ID NO: 28), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula:
(SEQ ID NO: 29)
YAibEGTFISDYSIALDK(Lys(R))HQQDFVNWLLAQRG-OH,
wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFISDYSIALDK(Lys(R))HQQDFVNWLLAQR-NH2 (SEQ ID NO: 30), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFISDYSIALDKIHQQ(Lys(R))FVNWLLAQR-NH2 (SEQ ID NO: 31), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFISDYSIALDKIHQQ(Lys(R))FVNWLLAQRPSSGAPPPS-NH2 (SEQ ID NO: 32), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFISDYSIALDKI(Lys(R))QQDFVNWLLAQRPSSGAPPPS-NH2 (SEQ ID NO: 33), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFISDYSIALDKIHQQDFVNWLLAQ(Lys(R))G-OH (SEQ ID NO: 34), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula:
(SEQ ID NO: 35)
YAibEGTFISDYS(Lys(R))ALDKIHQQDFVNWLLAQRG-OH,
wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFTSDYSIAibLDKIAQ(Lys(R))AFVQWLIAGGPSSGAPPPS-NH2 (SEQ ID NO: 36), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide is represented by formula: YAibEGTFTSDYSIAibLDKIAQ(Lys(R))AFVQWLIAGGPSSGAPPPS-NH2 (SEQ ID NO: 37), wherein (R) in (Lys(R)) represents a substituent, or a salt thereof.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide, or a salt thereof, has at least 90%, or at least 95%, or at least 99%, or at least 100% sequence identity to a peptide represented by formulas (I), (II), (III), (IV), (V), (VI), or (VII).

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide, or a salt thereof, has at least 95%, or at least 96%, or at least 97%, or at least 99%, or at least 100% sequence identity to a peptide represented by formulas (I), (II), (III), (IV), (V), (VI), or (VII).

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide, or a salt thereof, has at least 100% sequence identity to a peptide represented by formulas (I), (II), (III), (IV), (V), (VI), or (VII).

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The use of a GIP receptor agonist peptide of any one of claims 1 to 59, or a salt thereof, for the manufacture of a medicament for the treatment of emesis.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

A pharmaceutical composition for use in the treatment of emesis, the pharmaceutical composition comprising a GIP receptor agonist peptide of any one of claims 1 to 59, or a salt thereof.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, wherein the GIP receptor agonist peptide or a salt thereof, is formulated into medicament.

### Claim 63 (depends on 62)

The method according to claim 62, wherein the GIP receptor agonist peptide has a selectivity ratio of GLPr/GIPr of greater than 10, or greater than 100, or greater than 1,000.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-63, wherein the GIP receptor agonist peptide or medicament or pharmaceutical composition is administered to treat emesis as a monotherapy.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-63, wherein the emesis includes nausea and/or vomiting.

### Claim 66 (depends on 65)

The method according to claim 65, wherein the nausea and/or vomiting is a result of cyclic vomiting syndrome or chemotherapy.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1 to 59, and 62-63, wherein the subject is a non-type 2 diabetes mellitus subject.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-63, wherein the emesis is delayed emesis or anticipatory emesis.

### Claim 69 (depends on 1, 60, 62, 65)

The method of claim 1, the use of claim 60, the medicament of claim 62, or the method of claim 65, where the vomiting or the nausea is caused by one or more conditions or causes selected from the following (1) to (10):
(1) Diseases accompanied by vomiting or nausea such as gastroparesis, gastrointestinal hypomotility, peritonitis, abdominal tumor, constipation, gastrointestinal obstruction, chronic intestinal pseudo-obstruction, functional dyspepsia, cyclic vomiting syndrome, chronic unexplained nausea and vomiting, acute pancreatitis, chronic pancreatitis, hepatitis, hyperkalemia, cerebral edema, intracranial lesion, metabolic disorder, gastritis caused by an infection, postoperative disease, myocardial infarction, migraine, intracranial hypertension, and intracranial hypotension (e.g., altitude sickness);
(2) Vomiting and/or nausea induced by chemotherapeutic drugs such as (i) alkylating agents (e.g., cyclophosphamide, carmustine, lomustine, chlorambucil, streptozocin, dacarbazine, ifosfamide, temozolomide, busulfan, bendamustine, and melphalan), cytotoxic antibiotics (e.g., dactinomycin, doxorubicin, mitomycin-C, bleomycin, epirubicin, actinomycin D, amrubicin, idarubicin, daunorubicin, and pirarubicin), antimetabolic agents (e.g., cytarabine, methotrexate, 5-fluorouracil, enocitabine, and clofarabine), vinca alkaloids (e.g., etoposide, vinblastine, and vincristine), other chemotherapeutic agents such as cisplatin, procarbazine, hydroxyurea, azacytidine, irinotecan, interferon α, interleukin-2, oxaliplatin, carboplatin, nedaplatin, and miriplatin; (ii) opioid analgesics (e.g., morphine); (iii) dopamine receptor D1D2 agonists (e.g., apomorphine); (iv) cannabis and cannabinoid products including cannabis hyperemesis syndrome;
(3) Vomiting or nausea caused by radiation sickness or radiation therapy for the chest, the abdomen, or the like used to treat cancers;
(4) Vomiting or nausea caused by a poisonous substance or a toxin;
(5) Vomiting and nausea caused by pregnancy including hyperemesis gravidarium;
(6) Vomiting and nausea caused by a vestibular disorder such as motion sickness or dizziness;
(7) Opioid withdrawal;
(8) Pregnancy including hyperemesis gravidarium;
(9) A vestibular disorder such as motion sickness or dizziness; and
(10) A physical injury causing local, systemic, acute or chronic pain.

### Claim 70 (depends on 69)

The method according to claim 69, wherein the emesis is caused by cyclic vomiting syndrome or administration of a chemotherapeutic agent or chemotherapy.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the GIP receptor agonist peptide further comprises a modification by fatty acid addition at an epsilon amino group of at least one lysine residue.

### Claim 72 (depends on 71)

The method according to claim 71, wherein the modification is the linking of a C-16 palmitate group to the epsilon amino group of a lysine residue.

### Claim 73 (depends on 72)

The method according to claim 72, wherein the lysine residue is selected from the group consisting of: Lys16, Lys20, Lys37, and Lys40.

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, wherein the GIP receptor agonist peptide is formulated as a medicament comprising a GIP receptor agonist peptide, or a salt thereof and at least one pharmaceutically acceptable excipient.

### Claim 75 (depends on 74)

The method according to claim 74, wherein the medicament selectively activates the GIP receptor over the GLP receptor.

### Claim 76 (depends on 75)

The method according to claim 75, wherein the medicament has a selectivity ratio of (GLPr EC50/GIPr EC50) of greater than 10.

### Claim 77 (depends on 76)

The method according to claim 76, wherein the medicament has a selectivity ratio of (GLPr EC50/GIPr EC50) of greater than 100.

### Claim 78 (depends on 77)

The method according to claim 77, wherein the medicament has a selectivity ratio of (GLPr EC50/GIPr EC50) of greater than 1000.

### Claim 79 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-78, wherein the emesis is delayed emesis.

### Claim 80 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-79, wherein the emesis is anticipatory emesis.

### Claim 81 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-80, wherein emesis is treated in the subject without inducing anxiety or sedation in the subject.

### Claim 82 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-81, wherein emesis is treated in the subject without inducing suppression of glucagon secretion when plasma glucose levels are above fasting levels.

### Claim 83 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-82, wherein emesis is treated in the subject without substantially activating the GLP-1 receptor.

### Claim 84 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method according to any one of claims 1 to 62, wherein emesis is treated in the subject without concomitant, subsequent, or prior administration of a GLP-1 receptor agonist.

### Claim 85 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-82, wherein emesis is treated in a subject not taking a medicament to control a metabolic syndrome disorder.

### Claim 86 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-82, wherein emesis is treated in a subject taking a medicament to control a metabolic syndrome disorder.

### Claim 87 (depends on 85, 86)

The method according to any one of claim 85 or 86, wherein the metabolic syndrome disorder is type 2 diabetes mellitus or obesity.

### Claim 88 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-87, wherein the GIP receptor agonist peptide is a suppressant for vomiting or nausea.

### Claim 89 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-88, wherein the emesis is caused by or causes cyclic vomiting syndrome, or nausea or vomiting associated with administration of a chemotherapeutic agent.

### Claim 90 (depends on 89)

The method according to claim 89, wherein the chemotherapeutic agent comprises: (i) alkylating agents (e.g., cyclophosphamide, carmustine, lomustine, chlorambucil, streptozocin, dacarbazine, ifosfamide, temozolomide, busulfan, bendamustine, and melphalan), cytotoxic antibiotics (e.g., dactinomycin, doxorubicin, mitomycin-C, bleomycin, epirubicin, actinomycin D, amrubicin, idarubicin, daunorubicin, and pirarubicin), antimetabolic agents (e.g., cytarabine, methotrexate, 5-fluorouracil, enocitabine, and clofarabine), vinca alkaloids (e.g., etoposide, vinblastine, and vincristine), other chemotherapeutic agents such as cisplatin, procarbazine, hydroxyurea, azacytidine, irinotecan, interferon α, interleukin-2, oxaliplatin, carboplatin, nedaplatin, and miriplatin; (ii) opioid analgesics (e.g., morphine); (iii) dopamine receptor D1D2 agonists (e.g., apomorphine); (iv) cannabis and cannabinoid products including cannabis hyperemesis syndrome.

### Claim 91 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method according to any one of claims 1 to 17, wherein the subject has type 2 diabetes mellitus.

### Claim 92 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-91, wherein the GIP receptor agonist peptide or medicament is administered subcutaneously, intravenously, intramuscularly, intraperitonealy, orally or via inhalation.

### Claim 93 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-92, wherein the effective amount of the GIP receptor agonist peptide administered to the subject is about 0.01 to 0.5 mg/kg/day, 0.1 to 5 mg/kg/day, 5 to 10 mg/kg/day, 10 to 20 mg/kg/day, 20 to 50 mg/kg/day, 10 to 100 mg/kg/day, 10 to 120 mg/kg/day, 50 to 100 mg/kg/day, 100 to 200 mg/kg/day, 200 to 300 mg/kg/day, 300 to 400 mg/kg/day, 400 to 500 mg/kg/day, 500 to 600 mg/kg/day, 600 to 700 mg/kg/day, 700 to 800 mg/kg/day, 800 to 900 mg/kg/day or 900 to 1000 mg/kg/day.

### Claim 94 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-93, wherein the subject is human.

### Claim 95 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-94, wherein the GIP receptor agonist peptide or medicament is administered to the subject before, during, or after the subject develops the disease-state.

### Claim 96 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-95, wherein the GIP receptor agonist peptide or medicament is administered to the subject 1-3 times per day or 1-7 times per week.

### Claim 97 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1 to 59, and 62-96, wherein the GIP receptor agonist peptide or medicament is administered to the subject for 1-5 days, 1-5 weeks, 1-5 months, or 1-5 years.
